The need for regulatable vectors for gene therapy for Parkinson's disease

Experimental Neurology

Volumn 209, Issue 1, 2008, Pages 30-33

  Cress, Dean E ^a  

^a INTREXON CORPORATION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS VECTOR; ALPHA SYNUCLEIN; AMINO ACID DECARBOXYLASE; COMPLEMENTARY RNA; GLIAL CELL LINE DERIVED NEUROTROPHIC FACTOR; GUANOSINE TRIPHOSPHATE CYCLOHYDROLASE I; LENTIVIRUS VECTOR; LEVODOPA; NEURTURIN; PARKIN; PARVOVIRUS VECTOR; SHORT HAIRPIN RNA; SONIC HEDGEHOG PROTEIN; TYROSINE 3 MONOOXYGENASE; VIRUS VECTOR;

ARTICLE; BLOOD BRAIN BARRIER; BRAIN REGION; CELL BASED GENE THERAPY; CLINICAL TRIAL; DISEASE COURSE; DISEASE DURATION; DOPAMINERGIC NERVE CELL; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; GENE CONSTRUCT; GENE EXPRESSION; GENE EXPRESSION REGULATION; GENE REPRESSION; GENE TECHNOLOGY; HUMAN; NERVE DEGENERATION; NEUROPATHOLOGY; NONHUMAN; ON OFF PHENOMENON; PARKINSON DISEASE; PRIORITY JOURNAL; PROMOTER REGION; SUBSTANTIA NIGRA; UNSPECIFIED SIDE EFFECT; VIRAL GENE DELIVERY SYSTEM; VIRAL GENE THERAPY;

ANIMALS; DOPAMINE; GENE THERAPY; GENETIC VECTORS; HUMANS; PARKINSON DISEASE;

EID: 37549057030     PISSN: 00144886     EISSN: 10902430     Source Type: Journal    
DOI: 10.1016/j.expneurol.2007.08.015     Document Type: Article

References (29)

1. Ariad. ARIAD grants commercial license to its patented ARGENT(TM) cell-signaling regulation technology for development of new cancer therapies. 2007a. http://phx.corporate-ir.net/phoenix.zhtml?c=118422&p=irol-newsArticle&ID=914602&highlight=Accessed May 8, 2007.
2. Ariad. ARIAD grants second commercial license to its patented ARGENT(TM) cell-signaling regulation technology for development of new cancer therapies. 2007b. http://phx.corporate-ir.net/phoenix.zhtml?c=118422&p=irol-newsArticle&ID=961685&highlight=Accessed May 8, 2007.
3. Bartus R. CERE-120: From Concept to Clinical Trials and Beyond. Phacilitate Cell and Gene Therapy Forum, Baltimore, MD (2007)
4. Björklund A., Kirik D., Rosenblad C., Georgievska B., Lundberg C., and Mandel R.J. Towards a neuroprotective gene therapy for Parkinson's disease: use of adenovirus, AAV and lentivirus vectors for gene transfer of GDNF to the nigrostriatal system in the rat Parkinson model. Brain Res. 886 (2000) 82-98
5. Carlsson T., Bjorklund T., and Kirik D. Restoration of the striatal dopamine synthesis for Parkinson's disease: viral vector-mediated enzyme replacement strategy. Curr. Gene Ther. 7 (2007) 109-120
6. Collier T.J., Lipton J., Daley B.F., Palfi S., Chu Y., Sortwell C., Bakay R.A., Sladek Jr. J.R., and Kordower J.H. Aging-related changes in the nigrostriatal dopamine system and the response to MPTP in nonhuman primates: diminished compensatory mechanisms as a prelude to parkinsonism. Neurobiol. Dis. 26 (2007) 56-65
7. Cress D.E., Padidam M., Kumar P., Chen J., Katakam A., Karzenowski D., Friz J., and Potter D. The RheoSwitch® platform for regulated gene expression for cell and gene therapy of neurodegenerative diseases. 36th Annual Society for Neuroscience Meeting, Atlanta, GA (2006) abstract 470.14
8. During M.J., Feigen A., Eidelberg D., Fitzsimons H., Bland R., Lawlor T.A., Young D., Tang C., Cox M., and Kaplitt M.G. Subthalamic GAD gene transfer improves brain metabolism associated with clinical recovery in Parkinson's disease. 36th Annual Society for Neuroscience Meeting, Atlanta, GA (2006) abstract 510.9
9. Eslamboli A. Assessment of GDNF in primate models of Parkinson's disease: comparison with human studies. Rev. Neurosci. 16 (2005) 303-310
10. Eslamboli A., Cummings R.M., Ridley R.M., Baker H.F., Muzyczka N., Burger C., Mandel R.J., Kirik D., and Annett L.E. Recombinant adeno-associated viral vector (rAAV) delivery of GDNF provides protection against 6-OHDA lesion in the common marmoset monkey (Callithrix jacchus). Exp. Neurol. 184 (2003) 536-548
11. Eslamboli A., Georgievska B., Ridley R.M., Baker H.F., Muzyczka N., Burger C., Mandel R.J., Annett L., and Kirik D. Continuous low-level glial cell line-derived neurotrophic factor delivery using recombinant adeno-associated viral vectors provides neuroprotection and induces behavioral recovery in a primate model of Parkinson's disease. J. Neurosci. 25 (2005) 769-777
12. Georgievska B., Kirik D., and Bjorklund A. Aberrant sprouting and downregulation of tyrosine hydroxylase in lesioned nigrostriatal dopamine neurons induced by long-lasting overexpression of glial cell line derived neurotrophic factor in the striatum by lentiviral gene transfer. Exp. Neurol. 177 (2002) 461-474
13. Georgievska B., Kirik D., and Bjorklund A. Overexpression of glial cell line-derived neurotrophic factor using a lentiviral vector induces time- and dose-dependent downregulation of tyrosine hydroxylase in the intact nigrostriatal dopamine system. J. Neurosci. 24 (2004) 6437-6445
14. Goverdhana S., Puntel M., Xiong W., Zirger J.M., Barcia C., Curtin J.F., Soffer E.B., Mondkar S., King G.D., Hu J., Sciascia S.A., Candolfi M., Greengold D.S., Lowenstein P.R., and Castro M.G. Regulatable gene expression systems for gene therapy applications: progress and future challenges. Mol. Ther. 12 (2005) 189-211
15. Gupta S., Schoer R.A., Egan J.E., Hannon G.J., and Mittal V. Inducible, reversible, and stable RNA interference in mammalian cells. Proc. Natl. Acad. Sci. U. S. A. 101 (2004) 1927-1932
16. Kordower J.H. In vivo gene delivery of glial cell line-derived neurotrophic factor for Parkinson's disease. Ann. Neurol. 53 Suppl 3 (2003) S120-S132 (discussion S132-S134)
17. Kordower J.H., Bloch J., Ma S.Y., Chu Y., Palfi S., Roitberg B.Z., Emborg M., Hantraye P., Deglon N., and Aebischer P. Lentiviral gene transfer to the nonhuman primate brain. Exp. Neurol. 160 (1999) 1-16
18. Kordower J.H., Emborg M.E., Bloch J., Ma S.Y., Chu Y., Leventhal L., McBride J., Chen E.Y., Palfi S., Roitberg B.Z., Brown W.D., Holden J.E., Pyzalski R., Taylor M.D., Carvey P., Ling Z., Trono D., Hantraye P., Deglon N., and Aebischer P. Neurodegeneration prevented by lentiviral vector delivery of GDNF in primate models of Parkinson's disease. Science 290 (2000) 767-773
19. Kumar M.B., Potter D.W., Hormann R.E., Edwards A., Tice C.M., Smith H.C., Dipietro M.A., Polley M., Lawless M., Wolohan P.R., Kethidi D.R., and Palli S.R. Highly flexible ligand binding pocket of ecdysone receptor: a single amino acid change leads to discrimination between two groups of nonsteroidal ecdysone agonists. J. Biol. Chem. 279 (2004) 27211-27218
20. Lawlor P.A. Gene therapy for Parkinson's disease. In: Kaplitt M.G., and During M.J. (Eds). Gene Therapy of the Central Nervous System: From Bench to Bedside (2006), Elsevier 91-108
21. McBride J.L., and Kordower J.H. Neuroprotection for Parkinson's disease using viral vector-mediated delivery of GDNF. Prog. Brain Res. 138 (2002) 421-432
22. Muramatsu S., Wang L., Ikeguchi K., Fujimoto K., Nakano I., and Ozawa K. Recombinant adeno-associated viral vectors bring gene therapy for Parkinson's disease closer to reality. J. Neurol. 249 Suppl 2 (2002) II36-II40
23. Palli S.R., Kapitskaya M.Z., Kumar M.B., and Cress D.E. Ecdysone receptor-based inducible gene regulation system. Eur. J. Biochem. 270 (2003) 1308-1315
24. Rosenblad C., Georgievska B., and Kirik D. Long-term striatal overexpression of GDNF selectively downregulates tyrosine hydroxylase in the intact nigrostriatal dopamine system. Eur. J. Neurosci. 17 (2003) 260-270
25. Sajadi A., Bauer M., Thony B., and Aebischer P. Long-term glial cell line-derived neurotrophic factor overexpression in the intact nigrostriatal system in rats leads to a decrease of dopamine and increase of tetrahydrobiopterin production. J. Neurochem. 93 (2005) 1482-1486
26. Sapru M.K., Yates J.W., Hogan S., Jiang L., Halter J., and Bohn M.C. Silencing of human alpha-synuclein in vitro and in rat brain using lentiviral-mediated RNAi. Exp. Neurol. 198 (2006) 382-390
27. Torres E.M., Monville C., Lowenstein P.R., Castro M.G., and Dunnett S.B. In vivo transgene expression from an adenoviral vector is altered following a 6-OHDA lesion of the dopamine system. Brain Res. Mol. Brain Res. 137 (2005) 1-10
28. Winkler C., Georgievska B., Carlsson T., Lacar B., and Kirik D. Continuous exposure to glial cell line-derived neurotrophic factor to mature dopaminergic transplants impairs the graft's ability to improve spontaneous motor behavior in parkinsonian rats. Neuroscience 141 (2006) 521-531
29. Zurn A.D., Widmer H.R., and Aebischer P. Sustained delivery of GDNF: towards a treatment for Parkinson's disease. Brain Res. Brain Res. Rev. 36 (2001) 222-229